Provided are a compound of Formula (I) as an FTO inhibitor with improved and selective FTO inhibition, a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.
Palladium-Catalyzed Direct Approach to α-Trifluoromethyl Alcohols by Selective Hydroxylfluorination of <i>gem</i>
-Difluoroalkenes
作者:Bin Zhang、Xiaofei Zhang、Jian Hao、Chunhao Yang
DOI:10.1002/ejoc.201800468
日期:2018.9.30
A mild and efficient synthesis of α‐trifluoromethyl alcohols derivatives was achieved via Pd‐catalyzed selective hydroxylfluorination of gem‐difluoroalkenes using NFSI as the fluoride source.
[EN] TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTI-BACTERIENS A BASE DE TETRAHYDROQUINOLINE TRICYCLIQUE
申请人:UPJOHN CO
公开号:WO2004031195A1
公开(公告)日:2004-04-15
The invention includes tetrahydroquinoline and related compounds of formula (I), and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.
Purinenucleoside derivative modified in 8-position and medical use thereof
申请人:Tatani Kazuya
公开号:US20070179115A1
公开(公告)日:2007-08-02
The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like.
In the formula, n is 1 or 2; R
A
is a hydrogen atom or a hydroxyl group; R
1
is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R
2
to R
4
, P
1
and Q represents a halogen atom, a cyano group or the like.
Benzo[ b ]thiophene-2-carboxamide derivatives as potent urotensin-II receptor antagonists
作者:Chae Jo Lim、Seong Eun Woo、Su Ik Ko、Byung Ho Lee、Kwang-Seok Oh、Kyu Yang Yi
DOI:10.1016/j.bmcl.2016.08.049
日期:2016.10
Members of a series of benzo[b]thiophene-2-carboxamide derivatives, possessing an N-(1-(3-bromo-4-(piperidin-4-yloxy)benzyl)piperidin-4-yl) group, were synthesized and evaluated as urotensin-II receptor antagonists. The results show that these substances have potent UT binding affinities. Observations made in a systematic SAR investigation of the effects of a variety of substituents (R(1) and R(2))
[EN] CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES<br/>[FR] DÉRIVÉS DE TRIAZOLOPYRIMIDONE INHIBANT LA CGAS
申请人:HOFFMANN LA ROCHE
公开号:WO2021233852A1
公开(公告)日:2021-11-25
The invention relates to a compound of formula (I), wherein R1-R3 and A1-A3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.